Cortexyme

company

About

Cortexyme is developing treatments for Alzheimer's and other degenerative disorders.

  • 11 - 50

Details

Last Funding Type
Series B
Last Funding Money Raised
$76M
Industries
Biotechnology,Health Care,Medical,Pharmaceutical
Founded date
Jan 1, 2012
Number Of Employee
11 - 50
Operating Status
Active

Cortexyme is a clinical stage pharmaceutical company developing therapeutics based on data supporting a new theory of the cause of Alzheimer's and other degenerative disorders. Cortexyme is targeting a specific, undisclosed pathogen tied to neurodegeneration. The target has been validated in a number of animal models and Cortexyme is currently testing several potential lead therapeutics in preclinical studies.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
3
$99M
Cortexyme has raised a total of $99M in funding over 2 rounds. Their latest funding was raised on May 31, 2018 from a Series B round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
May 31, 2018 Series B $76M 3 Sequoia Capital Detail
Apr 14, 2017 Debt Financing $8M 2 Detail
Jan 6, 2016 Series A $15M 1 Pfizer Detail

Investors

Number of Lead Investors
Number of Investors
2
4
Cortexyme is funded by 4 investors. Sequoia Capital and Verily are the most recent investors.
Investor Name Lead Investor Funding Round
Sequoia Capital Yes Series B
Verily Series B
Lamond Family Series B
Pfizer Debt Financing